Less than half of large employers currently cover the new generation of obesity drugs, but an additional 18% say they’re considering adding them amid surging interest.
Scores of drugs to treat cancer, cardiovascular disease and other ailments are in shortage, and experts agree the main cause is the underlying weakness of the generic drug industry.